Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Advances in Therapy
|
November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Nazzareno Galiè, Sean Gaine, Richard Channick, et al.
European Journal of Heart Failure
|
November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Stephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Circulation
|
April 16, 2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension
Kelly M Chin, Lewis J Rubin, Richard Channick, et al.
Journal of the American College of Cardiology
|
October 1, 2021
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Kelly M Chin, Olivier Sitbon, Martin Doelberg, et al.
American Heart Journal
|
January 21, 2014
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Kelly M Chin, David B Badesch, Ivan M Robbins, et al.
JMIR Research Protocols
|
April 13, 2021
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
Kim M Kerr, C Greg Elliott, Raymond L Benza, et al.
Journal of Racial and Ethnic Health Disparities
|
August 5, 2025
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Harrison W Farber, Murali M Chakinala, Anna R Hemnes, et al.
Chest
|
April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial
Kelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
European Journal of Heart Failure
|
January 12, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Maurice Beghetti, Richard N Channick, Kelly M Chin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
February 17, 2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Olivier Sitbon, Kelly M Chin, Richard N Channick, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Advances in Therapy
|
November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Nazzareno Galiè, Sean Gaine, Richard Channick, et al.
European Journal of Heart Failure
|
November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Stephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Circulation
|
April 16, 2019
Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension
Kelly M Chin, Lewis J Rubin, Richard Channick, et al.
Journal of the American College of Cardiology
|
October 1, 2021
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Kelly M Chin, Olivier Sitbon, Martin Doelberg, et al.
American Heart Journal
|
January 21, 2014
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study
Kelly M Chin, David B Badesch, Ivan M Robbins, et al.
JMIR Research Protocols
|
April 13, 2021
The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
Kim M Kerr, C Greg Elliott, Raymond L Benza, et al.
Journal of Racial and Ethnic Health Disparities
|
August 5, 2025
Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Harrison W Farber, Murali M Chakinala, Anna R Hemnes, et al.
Chest
|
April 30, 2018
Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial
Kelly M Chin, Mardi Gomberg-Maitland, Richard N Channick, et al.
European Journal of Heart Failure
|
January 12, 2019
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
Maurice Beghetti, Richard N Channick, Kelly M Chin, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
February 17, 2020
Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study
Olivier Sitbon, Kelly M Chin, Richard N Channick, et al.
Page
of 7